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Volume 46, Number 5 Abstracts 1081sion, body mass index), baseline alcohol consumption were independently
associated with AAA diagnosis (P  .03 for trend). There was a maximum
hazard ratio of 1.21 (95% confidence interval [CI], 0.78 to 1.87) for30.0
g (2 standard drinks) of daily alcohol consumption. The association for
highest levels of alcohol intake was 1.65 (95% CI, 1.03 to 2.64).
Comment: This is the first report to document an association between
alcohol consumption and AAA. The data convincingly demonstrate higher
levels of alcohol consumption increase the risk of AAA, even in patients
without pre-existing cardiovascular disease. Moderate alcohol consumption
may have some benefit in lowering the risk of ischemic heart disease.
However, higher levels of alcohol confer no benefit and actually appear
harmful to the cardiovascular system.
A sustained mortality benefit from screening for abdominal aortic
aneurysm
Kim LG, Scott AP, Ashton, HA. and the Multicentre Aneurysm Screening
Study Group. Ann Intern Med 2007;146:699-706.
Conclusions: The early mortality benefit of screening ultrasonography
in reducing abdominal aortic aneurysm (AAA)-related death is maintained
over the long term. Cost effectiveness for screening improves over time.
Summary: The authors sought to estimate the benefits of ultrasound
screening for AAA in terms of all-cause mortality and cost-effectiveness.
They compared AAA mortality in a group of patients invited to undergo
ultrasound screening vs a group that was not. Mean follow-up was 7 years.
This was a randomized trial of AAA screening that was conducted in four
centers in the United Kingdom (UK) using a population-based sample of
67,770 men aged 65 to 74 years. Patients with an AAA detected during
screening were entered into a surveillance program and offered surgery when
the aneurysm fulfilled predefined criteria. Cost analysis was performed using
unit costs from large samples applied to individual data. Mortality data were
obtained from the UK national database.
The hazard ratio for AAA mortality in the group invited for screening
compared with those not invited for screening was 0.53 (95% confidence
interval [CI], 0.42 to 0.68). In patients with normal results on initial
ultrasonography, the rupture rate of AAA was 0.54 ruptures (95% CI, 0.25
to 1.02 ruptures) per 10,000 person-years. The observed hazard ratio for all
cause mortality in the screened vs nonscreened men was 0.96 (95% CI, 0.93
to 1.00). Cost effectiveness analysis was estimated at US $19,500 (95% CI,
$12,400 to $39,800) per life-year gained based on aneurysm-related mor-
tality and $76,000 (95% CI, $33,000 to infinity) per life-year gained based
on all cause death.
Comment: This is a late analysis of data from The Multicentre Aneu-
rysm Screening Study (MASS) analyzing the effect of AAA screening on
mortality in older men. It shows the short- and intermediate-term benefits of
AAA screening continue in the longer term. An interesting side bit of data is
that in patients whose initial aortic diameter is 3 cm, aneurysm-related
death in the next 7 years is extraordinarily unusual. Additional screening
after an initial ultrasound with a negative result is not warranted for at least
up to 7 years after an initial negative result on a screening study.
The impact of postoperative discontinuation or continuation of
chronic statin therapy on cardiac outcome after major vascular surgery
Le Manach Y, Godet G, Coriat P, et al. Anesth Analg 2007;104:1326-33.
Conclusions: Discontinuation of chronic statin therapy after major
vascular surgery increases the risk of myocardial infarction. Statin therapy
should be reinstituted on the first postoperative day after major vascular
surgery.
Summary: Accumulating evidence indicates statins reduce periopera-
tive cardiac events. It is unknown when patients who receive chronic statin
therapy should resume statins after a major vascular procedure. The authors
sought to compare cardiac outcomes in patients receiving chronic statin
therapy who resumed statin therapy immediately postoperatively vs those
where statin therapy was discontinued, at least temporarily, during the
perioperative period. This was a retrospective analysis of a prospectively
maintained database. Included were patients who underwent infrarenal
aortic reconstruction for aneurysm or occlusive disease using endovascular
or open techniques. Patients were studied from January 2001 to December
2004. Patients undergoing emergency procedures were excluded.
Blood was obtained for troponin I measurements when the patient
arrived to the postanesthesia care unit and on the first, second, and third
postoperative days. Patients not chronically treated with statins were con-
sidered controls and did not receive perioperative statin therapy. Patients
chronically treated with statins were divided into two groups. The first was
the discontinuation group. These were 491 patients from January 2001 to
December 2003 in which the authors’ institution did not have specific
guidelines regarding postoperative statin re-administration. The continua-
tion group consisted of 178 patients from January 2004 where guidelines
were in place to continue statins up to the evening before surgery, with
resumption on the first postoperative day using either nasogastric or oral
administration. Intracohort (propensity score) and extracohort (Lee score)risk adjustments were performed to determine the significance of differences
in elevated troponin levels in the continuation vs discontinuation groups. A
troponin I level99th percentile or0.2 ng/mL was considered indicative
of myocardial necrosis.
In the discontinuation group, median delay between surgery and
resumption of statin therapy was 4 days, and in the continuation group, it
was 1 day (P  .001). With propensity score matching for likelihood of
preoperative treatment, the odds ratio associated with chronic statin treat-
ment to predict myonecrosis for patients with vs without early postoperative
statin resumption (continuation vs discontinuation groups) was 0.38 and
2.1 (relative risk reduction, 5.4; 95% confidence interval, 1.2 to 25.3, P 
.001). The odds ratio for myocardial necrosis after adjustment for the Lee
score was 0.38 in the continuation group and 2.1 in the discontinuation
group (P  .001). Postoperative statin withdrawal was an independent
predictor of postoperative elevated troponin levels (odds ratio, 2.9; 95%
confidence interval, 1.6 to 5.5).
Comment: Although this was not a randomized trial and it used
historic controls, the data suggest that early resumption of statin therapy in
patients chronically receiving statin therapy will reduce the incidence of
myocardial infarction. Although there was no difference in perioperative
mortality in the continuation vs discontinuation groups, perioperative myo-
cardial infarction in itself is an end point worth reducing. It has been
associated with greater risk of long-term death and with increased duration
of hospitalization. More and more evidence now suggests a deleterious
cardiac effect of withdrawing statin therapy in the perioperative period.
Partial thrombosis of the false lumen in patients with acute type B
aortic dissection
Tsai TT, Evangelista A, Nienaber CA. The International Registry of Acute
Aortic Dissection. N Engl J Med 2007;357:349-59.
Conclusion: After hospital discharge, patients with acute type B aortic
dissection and partial thrombosis of the false lumen are at increased risk of
death compared with patients with complete patency of the false lumen.
Summary: The International Registry of Acute Aortic Dissection
(IRAAD) tracks patients with acute aortic dissection at 22 aortic centers in
11 countries. This is a registry, and treatment during hospitalization is not
standardized but is conducted at the discretion of each patient’s physician
and institution.
Patients with acute aortic type B dissection have low in-hospital mor-
tality but survival rates after discharge range from 92% at 1 year to 48 to 82%
at 5 years. It has been suggested that patients with complete thrombosis of
the false lumen have improved outcomes compared with patients who have
a patent false lumen, with the patent false lumen thought to place the patient
at increased risk of aortic expansion and death (Am J Card 2001;87:1378-
82). The authors sought to determine the influence on mortality of partial
thrombosis of the false lumen. They defined partial thrombosis of the false
lumen as both flow and thrombus present in the false lumen.
Between 1996 and 2003, 201 patients with type B aortic dissection
were enrolled in IRAAD and survived to discharge from the hospital. The
authors developedmortality curves according to the status of the false lumen
(complete thrombosis vs partial thrombosis vs patent). False lumen status
was determined during the initial hospitalization. They used Cox propor-
tional hazard analysis to identify independent predictors of death on follow-
up.
There were 114 patients (56.7%) who, during the index hospitaliza-
tion, had a patent false lumen. Sixty-eight patients (33.8%) had partial
thrombosis of the false lumen, and 19 (9.5%) had complete thrombosis of
the false lumen. At 3 years, the mortality rate for patients with a patent false
lumen was 13.7%. The mortality rate for patients with partial thrombosis of
the false lumen was 31.6%, and mortality for those with complete thrombo-
sis was 22.6%  22.6% (median follow-up, 2.8 years; P  .003, log-rank
test). Postdischarge mortality was independently predicted by partial throm-
bosis of the false lumen (relative risk, 2.69; 95% confidence interval [CI],
1.45 to 4.98; P .002), a history of atherosclerosis (relative risk, 1.87; 95%
CI, 1.01 to 3.47; P  .05), and a history of aortic aneurysm (relative risk,
2.05; 95% CI, 1.07 to 3.93; P  .03).
Comment: The authors postulate their findings may reflect that a
patent false lumen is perfused by a proximal entry tear and then decom-
pressed through re-entry tears distally. When thrombus partially occludes
the lumen, these distal re-entry tears may be occluded, impeding outflow
and leading to an increase in mean arterial and diastolic pressure that results
in increased wall tension in the false lumen and increases the risk of aneurysm
expansion, with increased risk of rupture and redissection.
Sustained benefit at two years of primary femoral-popliteal stenting
compared with balloon angioplasty with optional stenting
Schillinger M, Sabeti S, Dick P, et al. Circulation 2007;115:2745-9.
Conclusions: At 2 years, there is a sustained morphologic benefit for
treatment of superficial femoral artery (SFA) obstructions using self-expand-
ing nitinol stents inserted primarily vs balloon angioplasty with optional
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stenting vs optional stenting at 2 years.
Summary: The authors previously published data from the angioplasty
vs stenting with nitinol stents in the superficial femoral artery (ABSOLUTE)
trial. At 1 year, there was benefit from primary stenting vs optional stenting
(N Engl J Med 2006;354:1879-88). The authors now report 2-year data on
restenosis and clinical outcomes of the original patient group.
There were 104 patients with clinical limb ischemia and SFA occlusions
originally entered into the study. At 2 years, 98 patients (94%) were available
for assessment of restenosis (50% by duplex ultrasound imaging) and for
assessment of clinical and hemodynamic outcome using ankle-brachial index
and treadmill walking distance. At 2 years, by an intention to treat analysis,
restenosis rates were 45.7% (21 of 46) in the primary stenting group vs
69.9% (36 of 52) in the optional stenting group (P  .031). Primary and
secondary (n 63) stenting were both superior to plain balloon angioplasty
(n  35) with respect to the occurrence of restenosis (49% vs 74.3%; P .028) using a treatment-received analysis. There was no statistical benefit in
the primary stent group towards better treadmill walking (average 302 vs
196 m; P  .12) or any significant improvement in ankle-brachial index
values in the primary stented vs optional stented group (average, 0.88 vs
0.78; P  .09). There was no difference in intervention rate in the primary
stenting (17 of 46 [37.0%]) vs optional stenting group (28 of 52 [53.8%]; P
 .14).
Comment: The authors put a favorable spin on their data by empha-
sizing a “trend” towards improved clinical benefit with primary vs optional
stenting. Nevertheless, statistically insignificant is still statistically insignifi-
cant. Although larger numbers may have shown improvement in clinical
benefit with primary stenting vs optional stenting, a 45% restenosis rate in
stented patients at 2 years without clear clinical benefit indicates percutane-
ous treatment of SFA occlusive lesions is still not very good treatment of SFA
occlusive lesions.
